Join Richmond Pharmacology at this year�s Cardiovascular Safety in Drug Development: State-of-the-Art Assessments, taking place in Washington, USA from April 14 to 15.Featured topics will include QT issues in drug development, New approaches to QT analysis, Phase 3 development when there is a QT signal, Post-marketing surveillance, Ischemic events, Bleeding, Blood pressure and In what situations outcomes studies are necessary.Richmond Pharmacology�s CEO, Dr Jorg Taubel will be presenting the abstract; Can Food Serve as a Non-pharmacological Control in Thorough Cardiac Safety Studies, on Day 1, Session 3. This presentation will provide an insight into the effect of food on heart rate under the conditions of a Thorough QT (TQT) study. Dr Taubel has worked in clinical pharmacology for over 20 years and has been involved in the conduct of more than 400 early phase studies.For a detailed schedule of the meeting please click hereChaired by Dr Philip T. Sager, the meeting will feature presentations and commentary from leading industry, academic and regulatory speakers with advice on how to optimize cardiovascular safety assessment. For information on how to register for the conference click hereIf you would like to meet with Dr Taubel to discuss your QT requirements and how Richmond Pharmacology can help develop your program please email us at firstname.lastname@example.org and we will try our best to accommodate your request. Be assured that your study will be managed by experts with unparalleled clinical excellence.We hope to see you in Washington to learn more about Richmond Pharmacology and what you can expect from Europe�s leading Early Phase Full-Service CRO.